Table 5 Genotype distribution and allelic frequency of IL-6 (−174G/C) in controls and patients with ovarian cancer according to ages subtypes

IL-6 (−174G/C) Genotype (N, %)

 Age

45–55 y

 G/G

20 (60.6%)

14 (42.4%)

P < 0.05

1.0

 G/C

12 (36.4%)

2 (6.1%)

P < 0.05

0.24 (0.05–1.23)

 C/C

1 (3%)

17 (51.5%)

P < 0.05

24.29 (2.89–204.22)

 G

52 (79%)

30 (45%)

P < 0.05

0.224 (0.105–0.481)

 C

14 (21%)

36 (55%)

P < 0.05

4.457 (2.077–9.565)

 Dominant model (GC+CC vs. GG) GC+CC

13 (39.4%)

19 (57.6%)

NS

2.09 (0.78–5.57)

 Recessive model (CC vs. GG+GC) GG+GC

32 (97%)

16 (48.5%)

P < 0.05

1.0

 CC

1 (3%)

17 (51.5%)

P < 0.05

34.00 (4.15–278.81)

 Age

56–65 y

 G/G

9 (100%)

6 (75%)

NS

1.0

 G/C

0

0

–

–

 C/C

0 (0%)

2 (25%)

NS

0.368 (0.204–0.664)

 G

18 (100%)

12 (75%)

P < 0.05

1.0 (0.9–1.769)

 C

0 (0%)

4 (25%)

P < 0.05

1.3 (1.005–1.769)

 Dominant model (GC+CC vs. GG) GC+CC

0 (0%)

2 (25%)

NS

0.4 (0.215–0.743)

 Recessive model (CC vs. GG+GC) GG+GC

9 (100%)

6 (75%)

NS

1.0

 CC

0 (0%)

2 (25%)

NS

0.4 (0.215–0.743)

 Age

66–80y

 G/G

5 (83.3%)

3 (42.9%)

NS

1

 G/C

1 (16.7%)

1 (14.3%)

NS

1.67 ( 0.07–37.73)

 C/C

0 (0%)

3 (42.9%)

NS

2.00 (0.899–4.452)

 G

11 (92%)

7 (50%)

P < 0.05

0.09 (0.009–0.906)

 C

1 (8%)

7 (50%)

P < 0.05

11 (1.103–109.67)

 Dominant model (GC+CC vs. GG) GC+CC

1 (16.7%)

4 (57.1%)

NS

6.67 (0.49–91.33)

 Recessive model (CC vs. GG+GC) GG+GC

6 (100%)

4 (57.1%)

P < 0.05

1.00

 CC

0 (0%)

3 (42.9%)

NS

1.75 (0.721–3.324)